Hexaphlogin

Hexaphlogin is a prescription‑only intramuscular injection that contains the non‑steroidal anti‑inflammatory drug meloxicam; the exact strength is not disclosed. Marketed in the European Union, this COX‑2‑selective NSAID is formulated for systemic delivery via muscle tissue. Hexaphlogin is classified as an analgesic/anti‑inflammatory agent and is intended for use under medical supervision to manage pain and inflammatory conditions throughout the treatment period and to improve functional mobility in patients.

Hexaphlogin is indicated for the management of several painful and inflammatory musculoskeletal conditions, providing rapid systemic analgesia when oral administration is not feasible or when a faster onset of action is desired.

- Osteoarthritis pain and functional limitation. - Rheumatoid arthritis flare‑up pain and joint inflammation. - Acute musculoskeletal pain such as sprains, strains, or trauma‑related discomfort. - Post‑operative pain following orthopedic or soft‑tissue surgery. - Short‑term control of inflammatory pain when oral NSAIDs are unsuitable. - Management of chronic inflammatory conditions when rapid analgesia is required.

Like other NSAIDs, meloxicam may cause a range of adverse reactions, most of which are mild and reversible, while a few can be serious and require medical attention.

Common: - Gastrointestinal discomfort such as dyspepsia, nausea, or abdominal pain. - Headache or dizziness. - Mild elevation of liver enzymes. - Injection site reactions including pain, erythema, or swelling. - Transient increase in blood pressure. - Mild insomnia or sleep disturbance.

Serious: - Severe gastrointestinal ulceration or bleeding. - Cardiovascular events such as myocardial infarction or stroke. - Renal impairment or acute kidney injury. - Severe skin reactions like Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatotoxicity with marked elevation of transaminases.

Before prescribing Hexaphlogin, clinicians should evaluate patient-specific factors and consider several precautionary measures to minimize risk.

- Assess gastrointestinal history, especially ulcer disease or bleeding, before use. - Evaluate cardiovascular risk, including history of heart disease, hypertension, or stroke. - Review renal function; avoid in patients with severe impairment. - Use cautiously in elderly patients due to increased susceptibility to adverse effects. - Monitor liver enzymes during prolonged therapy. - Avoid in patients with known hypersensitivity to meloxicam or other NSAIDs. - Consider pregnancy and lactation status; safety data are limited.

Hexaphlogin may interact with other medicines; certain combinations should be avoided while others require careful monitoring.

Avoid: - Concurrent use with other NSAIDs or COX‑2 inhibitors, which can increase risk of gastrointestinal and cardiovascular toxicity. - Combination with anticoagulants (e.g., warfarin, direct oral anticoagulants) that may heighten bleeding risk. - Use with selective serotonin reuptake inhibitors (SSRIs) or other serotonergic agents, which can also elevate bleeding potential.

Use with caution: - Concomitant administration with antihypertensive agents, as meloxicam may attenuate blood‑pressure‑lowering effects. - Co‑administration with diuretics or ACE inhibitors in patients with renal impairment, requiring renal function monitoring. - Use with lithium therapy, as NSAIDs can increase lithium serum concentrations.